

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **July 8, 2013**

ELI LILLY AND COMPANY
(Exact name of registrant as specified in its charter)

Indiana
(State or Other Jurisdiction
of Incorporation)

Lilly Corporate Center
Indianapolis, Indiana
(Address of Principal
Executive Offices)

001-06351
(Commission
File Number)

35-0470950
(I.R.S. Employer
Identification No.)

46285
(Zip Code)

Registrant's telephone number, including area code: (317) 276-2000

No Change

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On July 8, 2013, John Lechleiter, Ph.D., resumed his position as the Company's chairman, president, and chief executive officer. As previously announced, Dr. Lechleiter had taken a medical leave

of absence beginning on May 6, 2013. Derica W. Rice, who served as acting chief executive officer during Dr. Lechleiter's absence, will resume his position as executive vice president, Global Services and chief financial officer. Ellen R. Marram, who served as interim chairperson of the Board of Directors, will resume her position as the board's lead independent director. A copy of the press release issued by the Company on July 8, 2013 is furnished as Exhibit 99.1.

(c) The information required under this Item is provided in paragraph 5.02(b) above and in the Company's definitive proxy statement for the 2013 annual meeting of stockholders filed with the SEC on March 25, 2013 and is herein incorporated by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibit 99.1 Press release issued by Eli Lilly and Company on July 8, 2013.

<u>Exhibit No.</u>	<u>Description of Document</u>
99.1	Press Release dated July 8, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ELI LILLY AND COMPANY
(Registrant)

By: /s/ Jamie E. Haney

Name: Jamie E. Haney

Title: Assistant Secretary and Counsel

Dated: July 8, 2013

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Document</u>
99.1	Press Release dated July 8, 2013

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.

www.lilly.com

Date: July 8, 2013

For Release: Immediately

Refer to: (317) 433-9899 - Edward Sagebiel; egs@lilly.com
(317) 276-5795 - Mark Taylor; taylor_mark_e@lilly.com

Lilly Announces Dr. Lechleiter's Return

INDIANAPOLIS, July 8, 2013-Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., has returned to his duties as chairman, president, and chief executive officer. Lechleiter has been on medical leave since his scheduled surgery for a dilated aorta on May 13, 2013. Lechleiter's surgery and recovery were successful and he has been cleared by his personal physician and the company's employee health services physician to return to full-time work.

"I am overwhelmed and humbled by the tremendous support and well-wishes I have received from my friends and fellow Lilly colleagues around the world," Lechleiter said. "I return to Lilly with renewed energy and enthusiasm, along with a new perspective on health and wellness and the critical importance of new medicines in advancing patient care.

"I want to thank and acknowledge Derica Rice for the important role he played during my absence, as well as Ellen Marram for her leadership of the Lilly board," added Lechleiter.

Derica W. Rice will continue in his role as executive vice president, global services and chief financial officer. Rice had assumed the additional role of acting chief executive officer during Lechleiter's medical leave. Ellen R. Marram will continue in her role as the board's lead independent director after serving as acting chairperson of the board of directors during Lechleiter's medical leave.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

#